Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 702 participants.

Also called NCT05920005

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 702 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05920005
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Brazil (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05920005. Randomized; quadruple masking; primary purpose treatment. Start 2023-08-22 (actual); primary completion 2025-03-31 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension
Acronym
OPTION TREAT
Condition
Hypertension
Intervention (Drug)
candesartan cilexetil + chlorthalidone + amlodipine
Intervention (Drug)
Exforge HCT® (valsartan 160mg + hydrochlorothiazide 12.5mg + amlodipine 5mg)
Lead sponsor
Hospital Israelita Albert Einstein (class: other)
Collaborator
Libbs Farmacêutica LTDA (class: industry)

Record details

Record id
cardio:ct-nct05920005
Content hash
64022ccb21f80e604520dbfcb6ae5e2d3247e66ae4bdd12a3eb6dfe9d0ca253c